This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

David Sobek

Contributor

Sobek writes on biotech, with a focus on small-cap oncology and antibiotics companies. He received a PhD in political science from Penn State in 2003. He is the proprietor of Sobek Analytics.


David Sobek
By This Author:
« Back
Page 1 of 6

Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

By David Sobek

The 2015 biotech stock predictions of TheStreet contributor David Sobek.

10:42AM 01/09/15

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses

By David Sobek

Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.

09:35AM 12/18/14

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

By David Sobek

Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.

11:17AM 11/19/14

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

By David Sobek

The diversification away from Xtandi has only just begun.

08:00AM 11/05/14

Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths

By David Sobek

Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.

09:35AM 10/15/14

Acceleron Hit Over Competitive Concerns, but Investors Overlook Rest of Pipeline

By David Sobek

An Acceleron update in December could reignite investor interest in the stock.

09:21AM 10/02/14

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

By David Sobek

The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.

08:26AM 09/17/14

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

By David Sobek

The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

09:36AM 09/10/14

Tetraphase Oral Antibiotic Data Look Good

By David Sobek

Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.

06:30AM 09/03/14

Previewing Tetraphase Oral Antibiotic Study Results

By David Sobek

Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.

08:00AM 08/27/14

« Back
Page 1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs